King Altace Physician Promotion Emphasized For 2001; DTC Delayed To 2002
Executive Summary
King Pharmaceuticals will dedicate its entire $90 mil. Altace marketing campaign to physician-directed promotions following deferment of the ACE inhibitor's DTC advertising campaign.
You may also be interested in...
King Files 20 Levoxyl Patent Applications; Sales Up 65% to $27 Mil. In Q3
King has filed 20 patent applications for Levoxyl (levothyroxine) to extend exclusivity for the thyroid hormone product, the company said during an Oct. 29 earnings call
King Files 20 Levoxyl Patent Applications; Sales Up 65% to $27 Mil. In Q3
King has filed 20 patent applications for Levoxyl (levothyroxine) to extend exclusivity for the thyroid hormone product, the company said during an Oct. 29 earnings call
FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002
An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.